R&D News | pharmaphorum

News

Immunovant's thyroid eye disease drug flunks pivotal trials

Immunovant shares were sliding today after it reported that FcRn blocker batoclimab failed a pair of phase 3 trials in thyroid eye disease.

News

AZ claims another win for Imfinzi in frontline liver cancer

AstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme.

News

Alzheimer's biotech Korsana to go public via reverse merger

By merging with Cyclerion, Korsana will get a Nasdaq listing and additional cash to develop its new-generation amyloid-targeting drug for Alzheimer's.

News

EMA seeks input on virtual alternative to animal test

EMA delivers a milestone in the replacement of animals in drug testing with the qualification of a virtual model for repeat-dose toxicity studies.

News

Eli Lilly makes $7.8bn takeover play for Centessa

Sleep disorder specialist Centessa is heading for an acquisition by Eli Lilly, which has offered $6.3bn for the US and UK-based biotech.

News

AZ considers filings for long-acting Strensiq follow-up

AstraZeneca's long-acting Strensiq follow-up efzimfotase alfa has hit the mark in children with rare disease HPP, but the data in adults is unclear.

Immunovant's thyroid eye disease drug flunks pivotal trials

AZ claims another win for Imfinzi in frontline liver cancer

Alzheimer's biotech Korsana to go public via reverse merger

EMA seeks input on virtual alternative to animal test

Eli Lilly makes $7.8bn takeover play for Centessa

AZ considers filings for long-acting Strensiq follow-up

ESMO26: VOLGA stirs up perioperative bladder cancer therapy

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks